The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma

Glioblastoma (GB) incidence is about 2 –3 cases per 100,000 people [1], and its prognosis is extremely poor with a median survival time of only 14.5 months from diagnosis in clinical trials [2] with 3-year survival rates rarely reaching 5% [3]. However, in clinical practice, a great variability in terms of prognosis exists in unselecte d patients. Extensive characterisation by multiple omic platforms is improving our knowledge of the molecular bases underlying the nature of GB aggressiveness [4,5].
Source: Clinical Neurology and Neurosurgery - Category: Neurosurgery Authors: Source Type: research